PACB:
Analysis & Opinions
-
January 07, 2013
Roche may have walked away from Illumina for good.
-
August 31, 2012
Although this has been a solid year for med-tech, some sub-sectors are starting to lag a bit during this late summer ...
-
November 30, 2011
It may be time to consider Life Tech as a good blue-chip play in the health-care sector.
-
October 10, 2011
Illumina and competitors get hit by weak academic spending. Optimism remains, however, with the pull of new and ...
-
August 04, 2011
Illumina's sky-high valuation takes a beating on lower guidance.
-
July 07, 2011
Affymetrix continues to flounder with unexciting technology.
-
April 29, 2011
Illumina is a torrid grower, and growth investors seem to be willing to pay any price.
-
November 18, 2010
Recent life sciences IPOs have landed with thud, which is a drastic contrast to the trends that were occuring just ...
-
August 23, 2010
Last week saw two major developments in one of the fastest-growing arenas of life science.
